When your patients with multiple myeloma relapse offer them a chance …

  • … to control their disease.§*,1–4
  • … and live longer.#*,5,6
  • … while preserving their quality of life.*,7,8

Give your patients a better chance for a longer life – with Kyprolis*,5,6

For full safety information please refer to the SmPC, incl special warnings and precautions

References

  1. Stewart AK, et al. N Engl J Med 2015;372:142–152.: ≥CR in ITT population KRd 31.8%, Rd 9.3% Median PFS in ITT population KRd 26.3 mos, Rd 17.6 mos
  2. Dimopoulos MA, et al. Blood Cancer Journal (2017) 7, e554: 1 prior therapy ≥CR KRd 33.7%, Rd 7.0%; Median PFS : KRd 29.6 mos, Rd 17.6 mos
  3. Dimopoulos MA, et al. Lancet Oncol 2016;17:27–38. ≥CR in ITT population Kd 13%, Vd 6% Median PFS in ITT population Kd 18.7 mos, Vd 9.4 mos
  4. Moreau P et al., Leukemia 2016; 1-8: 1 prior therapy ≥CR Kd 11.7%, Vd 7.8%; Median PFS : Kd 22.2 mos, Vd 10.1 mos
  5. Siegel et al, J Clin Oncol 2018;36(8):728–734. Median OS: KRd 48.3 mo, Rd 40.4 mo, HR=0.79, P=0.01
  6. Dimopolous et al. Lancet 2017 Oct;18(10):1327-1337: Median OS: Kd 47.6 mo, Vd 40 mo, HR=0.79, P=0.01
  7. Stewart AK, et al. J Clin Oncol 2016;34:3921-3930.
  8. Ludwig H, et al. Presented at ASH 58th Annual Meeting & Exposition; 3-6 December 2016; San Diego, CA. Abstract 3309.

Terms of Use

The information contained in this site is for European healthcare professionals only.

Kyprolis